Examples of 10- and 20-y absolute risk estimates for breast, endometrial, and ovarian cancer using SEER rates corrected for hysterectomy for endometrial cancer and for oophorectomy for ovarian cancer in non-Hispanic, white women.

<p>C, current; F, former; N, no; NA, not applicable; Y, yes.</p

Study populations and exclusions for model development: NIH-AARP and PLCO cohorts at baseline.

<p>Study populations and exclusions for model development: NIH-AARP and PLCO cohorts at baseline.</p

Breast cancer risk predictions during the follow-up of non-Hispanic, white women in the NHS for new breast cancer model and BCRAT.

<p>NA, not applicable.</p

Selected characteristics of non-Hispanic, white women in the NIH-AARP and PLCO cohorts.

<p>NA, not applicable.</p

Study population and exclusions for model validation: NHS cohort at baseline.

<p>Study population and exclusions for model validation: NHS cohort at baseline.</p

Age-specific incidence per 100,000 person-years in non-Hispanic white women from the NHS cohort, excluding only women with prevalent cancer of interest and no positive follow-up time.

a<p>Cancer of the corpus uteri or uterus, not otherwise specified.</p

Endometrial and ovarian cancer risk prediction during the follow-up of non-Hispanic, white women in the NHS.

<p>Endometrial and ovarian cancer risk prediction during the follow-up of non-Hispanic, white women in the NHS.</p

5-y age-specific SEER incidence rates, 1992–2006, for breast, endometrial, and ovarian cancers for white, non-Hispanic females in 13 SEER registries (Alaska excluded) that cover 14% of the US population.

<p>Source: SEER (<a href="http://seer.cancer.gov/" target="_blank">http://seer.cancer.gov/</a>).</p>a<p>Cancer of the corpus uteri or uterus, not otherwise specified.</p

Multivariate relative risk estimates for breast, endometrial, and ovarian cancer among non-Hispanic, white women in the NHS validation cohort.

<p>Categories for variables fitted with a trend: All variables are coded so that the lowest risk category is the reference category. BMI: <25, 25 to <30, 30 to <35, and 35+ kg/m² for breast cancer and <25, 25 to <30, 30 to <35, 35 to <40, and 40+ kg/m² for endometrial cancer; estrogen and progestin MHT use: never, <10 y, 10+ y; other/unknown MHT use: no, yes; MHT use: never, <10 y, 10+ y; age at first birth: <25, 25–29, and 30+ y; parity: 0, 1–2, and 3+ children for endometrial and ovarian cancer; age at menopause: <50, 50–54, 55+ y, missing; benign breast disease/biopsy: no, yes, missing; alcohol consumption: 0, <1, 1+ drinks/day.</p